Treace John T. bought 49,810 shares of TREACE MEDICAL CONCEPTS, INC. at $2.87 for $143k on May 27, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Chief Executive Officer
Chief Executive Officer
Filed May 28, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$143,188.81Shares × reported price
Shares traded
49,810Common Stock
Price per share
$2.87Reported price. Read footnotes for ranges.
% of reported position traded
0.7%This security and ownership context
Holdings after
7,212,631Direct
Trade date
May 27, 2026Buy
Filed
May 28, 2026, 4:33 PM ET1-day reporting delay
Accession
0001193125-26-245341Code P · Transaction 387468
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 7,162,821 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 26, 2026Buy4,508$2.79$12,575.97Trade 387467
May 28, 2026Buy61,202$3.02$184,823.92Trade 387469
3 transaction rows in this filing. Joint filers share the same rows.

TMCI price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TMCI · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −38%1w ago −8.4%1d ago −8.1%
Returns since7d +20%30d +45%90d +53%180d1y

Footnotes in full

F1: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $2.7600 to $2.8000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2: Includes 542,784 restricted stock units. F3: The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee. F4: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $2.7976 to $2.9400 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F5: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $2.8233 to $3.1150 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F6: The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee.